Amgen Inc.

AMGN

Held by 1 specialist biotech fund

Fund Holdings

“# SIGNAL NOTE: Eventide Initiates AMGN Position Eventide's $9.3M entry into Amgen likely reflects conviction in near-term catalysts, potentially including MariTide (obesity/GLP-1) Phase 3 readouts expected in 2025 or confidence in Amgen's diversified pipeline offsetting biosimilar headwinds in legacy franchises.”

AI analyst context — unlock full analysis

Catalysts

Phase 2May 17, 2016intensive chemotherapy and hematopoietic stem cell rescuePrimary Central Nervous System Lymphoma

Phase 2Jul 5, 2018carfilzomibSmoldering Multiple Myeloma

Phase 2Nov 30, 2019Consolidation with 4 cycles of CarCyDexMultiple Myeloma

Phase 2Jul 30, 2022CarfilzomibMultiple Myeloma

Phase 3PositiveAug 2, 2022AMG 510KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Phase 2Feb 7, 2023Talimogene LaherparepvecSoft Tissue Sarcoma

Phase 2Jun 28, 2023Carfilzomib, lenalidomide, dexamethasone (KRd) + DaratumumabMultiple Myeloma

Phase 2Sep 26, 2023CarfilzomibSmoldering Multiple Myeloma

Phase 2Jan 31, 2024CarfilzomibMultiple Myeloma, Smoldering Multiple Myeloma

Phase 2Feb 28, 2024BlinatumomabB-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood

Phase 3PositiveApr 9, 2024InebilizumabIgG4 Related Disease

Phase 3May 28, 2024inebilizumabMyasthenia Gravis

Phase 2Aug 1, 2024PanitumumabTreatment Related Cancer

Phase 3Sep 30, 2024IsatuximabMultiple Myeloma

Phase 3Jan 29, 2025TarlatamabSmall Cell Lung Cancer (SCLC)

Phase 2Mar 28, 2025TarlatamabExtensive Stage Small Cell Lung Cancer

Phase 2Apr 15, 2025IsatuximabMultiple Myeloma in Relapse, Multiple Myeloma, Refractory

Phase 2Jun 20, 2025Talimogene LaherparepvecSoft Tissue Sarcoma, Sarcoma,Soft Tissue

Phase 3Jun 20, 2025BemarituzumabGastric Cancer, Gastroesophageal Junction Adenocarcinoma

Phase 2Jun 24, 2025CarfilzomibPlasma Cell Myeloma

Phase 3Jun 28, 2025FOLFOX regimenColorectal Cancer

Phase 3Jul 16, 2025SotorasibColorectal Cancer (CRC)

Phase 2Jul 22, 2025Talimogene Laherparepvec (T-VEC)Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma

Phase 3Jul 31, 2025Carfilzomib Lenalidomide DexamethasoneMultiple Myeloma

Phase 2Aug 7, 2025RegorafenibColorectal Cancer

Phase 2Oct 6, 2025Maridebart CafraglutideType 2 Diabetes Mellitus (T2DM)

Phase 3Oct 14, 2025BemarituzumabGastric Cancer, Gastroesophageal Junction Adenocarcinoma

Phase 3Nov 19, 2025Erenumab Dose 1Migraine

Phase 3Nov 20, 2025ApremilastPlaque Psoriasis

Phase 2Nov 21, 2025BemarituzumabGastric Cancer, Gastroesophageal Junction Cancer

Phase 2Jan 5, 2026BlinatumomabB Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia

Phase 3Jan 14, 2026TeprotumumabThyroid Eye Disease

Phase 2Mar 19, 2026HZN-1116Sjogren's Syndrome

Phase 2Mar 31, 2026BlinatumomabAcute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive

Phase 2Apr 1, 2026AMG 193MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors

Phase 3May 20, 2026RomiplostimChemotherapy-induced Thrombocytopenia

Phase 2May 30, 2026sotorasibKRAS p.G12C Mutant Advanced Solid Tumors

Phase 2Jun 30, 2026AMG 193Advanced MTAP-null Solid Tumors

Phase 2Jun 30, 2026Blinatumomab 9ugAcute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia

Phase 3Jun 30, 2026SotorasibNon-Small Cell Lung Cancer (NSCLC)

Phase 2Jun 30, 2026avutometinib and sotorasibNon Small Cell Lung Cancer, KRAS Activating Mutation

Phase 2Jun 30, 2026DaratumumabMyeloma, Multiple Myeloma

Phase 3Jul 14, 2026TezepelumabEosinophilic Esophagitis

Phase 3Aug 6, 2026ApremilastPlaque Psoriasis

Phase 3Aug 19, 2026DazodalibepSjogren's Syndrome

Phase 3Sep 30, 2026PrednisoneAcute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma

Phase 2Oct 19, 2026RocatinlimabAsthma

Phase 3Oct 22, 2026DazodalibepSjögren's Syndrome (SS)

Phase 3Oct 28, 2026RocatinlimabPrurigo Nodularis

Phase 3Dec 14, 2026ABP 234Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2Dec 30, 2026TarlatamabRelapsed/Refractory Small Cell Lung Cancer

Phase 2Dec 31, 2026RomiplostimLymphoma Patients, Thrombocytopenia

Phase 3Jan 15, 2027Ocrelizumab (US)Relapsing-remitting Multiple Sclerosis (RRMS)

Phase 3Jan 21, 2027Maridebart CafraglutideObesity

Phase 3Jan 21, 2027Maridebart cafraglutideType 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Phase 2Jan 31, 2027Trastuzumab + PaclitaxelHER2-positive Breast Cancer, Operable Breast Cancer

Phase 2Feb 1, 2027BortezomibMultiple Myeloma

Phase 2Feb 22, 2027AMG 732Thyroid Eye Disease

Phase 2Mar 2, 2027RomosozumabOsteoporosis, Post-menopausal

Phase 2Mar 31, 2027Romosozumab Prefilled Syringe [Evenity]Premenopausal Idiopathic Osteoporosis

Phase 2Apr 13, 2027InebilizumabNeuromyelitis Optica Spectrum Disorder

Phase 2Apr 15, 2027TarlatamabMetastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced High-grade MTC

Phase 3Apr 27, 2027Maridebart cafraglutideObesity Disease

Phase 2May 31, 2027DaratumumabMultiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse

Phase 3Jun 1, 2027RomosozumabOsteogenesis Imperfecta

Phase 3Jun 30, 2027EtelcalcetideSecondary Hyperparathyroidism

Phase 3Jun 30, 2027RocatinlimabAtopic Dermatitis

Phase 3Jul 5, 2027TarlatamabExtensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

Phase 2Aug 31, 2027TarlatamabMetastatic Prostate Cancer

Phase 3Sep 29, 2027Maridebart cafraglutideObstructive Sleep Apnea

Phase 3Sep 29, 2027Maridebart cafraglutideObesity, Obstructive Sleep Apnea

Phase 2Sep 29, 2027Maridebart cafraglutideOverweight or Obesity and Elevated Liver Fat

Phase 3Sep 30, 2027BlinatumomabAcute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

Phase 2Sep 30, 2027PanitumumabCancer, Tumors, Neoplasm

Phase 2Sep 30, 2027bemarituzumab, paclitaxel, ramucirumabMetastatic Gastro-esophageal Adenocarcinoma

Phase 2Oct 20, 2027AMG 510Lung Cancer

Phase 2Oct 31, 2027Interferon gamma-1bAcute Myeloid Leukemia, Myelodysplastic Syndromes

Phase 2Oct 31, 2027CarboplatinBreast Carcinoma, Breast Lump, Edema

Phase 2Nov 24, 2027BlinatumomabB Cell Precursor Acute Lymphoblastic Leukemia

Phase 2Nov 30, 2027BlinatumomabAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression

Phase 2Dec 31, 2027TarlatamabExtensive Stage Lung Small Cell Carcinoma

Phase 2Dec 31, 2027Treatment with blinatumomab given subcutaneously.Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia

Phase 2Dec 31, 2027TarlatamabExtrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma

Phase 2Jan 2, 2028SotorasibAdvanced Solid Tumors

Phase 2Jan 17, 2028InebilizumabSystemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis

Phase 3Jan 25, 2028ABP 206Melanoma

Phase 2Jan 29, 2028AMG 732Thyroid Eye Disease

Phase 3Jan 31, 2028FOLFIRI RegimenMetastatic Colorectal Cancer

Phase 3Feb 14, 2028ABP 234Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Phase 2Mar 3, 2028TarlatamabAstrocytic Tumor, Oligodendroglial Tumor

Phase 3Mar 21, 2028ApremilastActive Juvenile Psoriatic Arthritis

Phase 3Mar 31, 2028PlaceboAtherosclerotic Cardiovascular Disease

Phase 2Apr 24, 2028Tarlatamab treatmentDLL3-expressing Tumors, Advanced Tumors

Phase 3May 21, 2028Osteogenesis Imperfecta

Phase 3May 23, 2028PegloticaseUncontrolled Gout

Phase 3May 31, 2028TezepelumabAsthma

Phase 2May 31, 2028DexamethasoneAcute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

Phase 3Jun 2, 2028OlpasiranCardiovascular Disease

Phase 3Jun 30, 2028Maridebart CafraglutideAtherosclerotic Cardiovascular Disease, Overweight, Obesity

Phase 3Jun 30, 2028Maridebart cafraglutideHeart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

Phase 2Jul 1, 2028Belantamab mafodotinMultiple Myeloma, Relapse Multiple Myeloma

Phase 2Aug 31, 2028Carfilzomib + IbrutinibWaldenstrom Macroglobulinemia

Phase 3Sep 26, 2028AvacopanVasculitis

Phase 2Nov 29, 2028AMG 193MTAP-deleted NSCLC

Phase 2Dec 5, 2028BlinatumomabRelapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

Phase 2Dec 31, 2028DexamethasoneLymphoblastic Leukemia

Phase 2Dec 31, 2028TarlatamabAdvanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin

Phase 3Jan 2, 2029XaluritamigMetastatic Castration-resistant Prostate Cancer

Phase 3Jan 4, 2029TarlatamabSmall-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

Phase 2Jan 31, 2029Blinatumomab InjectionB-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL

Phase 3Jan 31, 2029EtelcalcetideSecondary Hyperparathyroidism, Chronic Kidney Disease

Phase 2Feb 9, 2029TarlatamabSmall Cell Lung Cancer (SCLC)

Phase 3Mar 13, 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)

Phase 2Apr 30, 2029Carfilzomib, Lenalidomide, Dexamethasone, Belantamab MafodotinMultiple Myeloma

Phase 2Aug 31, 2029Subcutaneous BlinatumomabCD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)

Phase 3Sep 7, 2029BlinatumomabNewly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Phase 2Oct 31, 2029TarlatamabExtensive Stage Lung Small Cell Cancer

Phase 2Oct 31, 2029TarlatamabGlioma, CNS Tumor, Adult, CNS Tumor, Childhood

Phase 3Dec 11, 2029DazodalibepSjögren's Syndrome

Phase 3Jan 7, 2030XaluritamigMetastatic Castration-resistant Prostate Cancer

Phase 3Feb 7, 2030ApremilastBehçet Disease

Phase 2Mar 13, 2030InebilizumabGeneralized Myasthenia Gravis

Phase 3May 10, 2030BlinatumomabPhiladelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia

Phase 3May 29, 2030TarlatamabLimited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

Phase 2May 31, 2030TarlatamabMelanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma

Phase 3Jul 31, 2030AvacopanGranulomatosis With Polyangiitis, Wegener's, GPA

Phase 2Oct 12, 2030BlinatumomabPhase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia

Phase 2Jun 10, 2031InebilizumabImmunoglobulin G4-related Disease

Phase 2Sep 30, 2031BlinatumomabPhase II Clinical Trial, Blinatumomab, Olverembatinib

Phase 2Sep 30, 2031BlinatumomabB-cell Acute Lymphoblastic Leukemia

Phase 3Oct 20, 2031OlpasiranCardiovascular Disease

Phase 3Jun 30, 2033Omitted DoxorubicinLeukemia, Acute Lymphoblastic

Phase 3Mar 17, 2036ApremilastBehçet's Disease, Juvenile Psoriatic Arthritis

Unlock Full AMGN Analysis

Dollar amounts and share counts for all 1 fund positions
AI-generated context explaining why each position matters
Insider buy/sell details with names, titles, and amounts

Start 7-Day Free Trial — $29/mo

No credit card required

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 28,372Value: $9.3M

# SIGNAL NOTE: Eventide Initiates AMGN Position Eventide's $9.3M entry into Amgen likely reflects conviction in near-term catalysts, potentially including MariTide (obesity/GLP-1) Phase 3 readouts expected in 2025 or confidence in Amgen's diversified pipeline offsetting biosimilar headwinds in legacy franchises. The timing aligns with AMGN's valuation compression relative to peers and potential upside from non-obesity assets (e.g., Tezepelumab in atopic dermatitis, cardiometabolic programs). This signals values-focused biotech allocators see technical oversold conditions with meaningful probability-weighted upside in 2025.

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial